Johnson & Johnson Reports 2020 Third-Quarter Results
New Brunswick, N.J. (October 13, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2020. “Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals,” said Alex Gorsky, Chairman and Chief Executive Officer. “I am proud of the relentless passion and Credo-led commitment to patients and customers that our colleagues around the world continue to demonstrate as we boldly fight the COVID-19 pandemic. Our wo...
Source: Johnson and Johnson - October 13, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news
Experts Assess Infection Risks for Patients on Biologics Experts Assess Infection Risks for Patients on Biologics
A group of experts have summarized and made recommendations about recent findings regarding infections that can occur during treatment for rheumatoid arthritis and psoriatic arthritis.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - October 8, 2020 Category: Infectious Diseases Tags: Rheumatology News Source Type: news
Pregnancy Studies on Psoriasis, PsA Medications Pick Up Pregnancy Studies on Psoriasis, PsA Medications Pick Up
Pregnancy outcomes data are increasingly emerging but dermatologists, rheumatologists, and their female patients with psoriasis and psoriatic arthritis (PsA) want much more.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - October 2, 2020 Category: Dermatology Tags: Ob/Gyn & Women ' s Health News Source Type: news
SIMPONI ARIA ® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Global Head, Jans...
Source: Johnson and Johnson - September 30, 2020 Category: Pharmaceuticals Source Type: news
Simponi Aria (golimumab) Approved by the FDA for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
HORSHAM, PA, September 30, 2020– The Janssen Pharmaceutical Companies of Johnson& Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved Simponi Aria (golimumab) for patients 2 years of age and older for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 30, 2020 Category: Drugs & Pharmacology Source Type: news
Secukinumab Not Superior to Adalimumab in Psoriatic Arthritis
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - September 26, 2020 Category: Orthopaedics Tags: Snapshot Source Type: news
Key discovery in psoriatic arthritis points way for developing targeted treatments
(University of Oxford) The strongest evidence yet of a single cause for psoriatic arthritis has been discovered by researchers. The disease may be activated by the same trigger in different patients which, if identified, could move towards creating therapies that would prevent psoriatic arthritis, and potentially providing a cure. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 21, 2020 Category: International Medicine & Public Health Source Type: news
The Long Road to a PsA Prevention Trial The Long Road to a PsA Prevention Trial
About one third of all patients with psoriasis will develop psoriatic arthritis in their lifetime. With no definitive blood test for diagnosis, prevention trials are key to identifying high-risk groups.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 5, 2020 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news
Ixekizumab in psoriatic arthritis: more QALYs, lower cost in Spain
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - August 31, 2020 Category: Drugs & Pharmacology Source Type: news
Tumor Necrosis Factor Alpha Inhibitors May Pose Risk in Ankylosing Spondylitis and Psoriatic Arthritis
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - August 21, 2020 Category: Orthopaedics Tags: Snapshot Source Type: news
Johnson & Johnson Reports 2020 Second-Quarter Results
New Brunswick, N.J. (July 16, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2020. “Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment,” said Alex Gorsky, Chairman and Chief Executive Officer. “Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic and save lives....
Source: Johnson and Johnson - July 16, 2020 Category: Pharmaceuticals Source Type: news
FDA Approves Tremfya (Guselkumab) for Psoriatic Arthritis FDA Approves Tremfya (Guselkumab) for Psoriatic Arthritis
Guselkumab, first approved for adults with plaque psoriasis in 2017, has now been approved for adults with active psoriatic arthritis (PsA). The FDA based its approval on two pivotal phase 3 trials.FDA Approvals (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - July 15, 2020 Category: Dermatology Tags: Rheumatology News Source Type: news
TREMFYA ® (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
HORSHAM, PA, July 14, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.[1],[2] TREMFYA is the first treatment approved for active PsA that selectively inhibits interleukin (IL)-23, a naturally occurring cytokine that is involved in normal inflammatory and immune responses associated with the symptoms of PsA. The safety and efficacy of TREMFYA in PsA have been dem...
Source: Johnson and Johnson - July 14, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
TREMFYA(R) (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
In two Phase 3 clinical trials, TREMFYA significantly improved signs and symptoms in joints, skin and soft tissue in adults with active psoriatic arthritis
TREMFYA is the first and only biologic approved for the treatment of active psoriatic arthritis t... Biopharmaceuticals, FDA Janssen Pharmaceutical, Johnson & Johnson, TREMFYA, guselkumab, PsA (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 14, 2020 Category: Pharmaceuticals Source Type: news
